Basal Cell Carcinoma

Basal cell carcinoma (BCC) is the most common form of skin cancer, often caused by prolonged exposure to ultraviolet (UV) radiation from the sun. In Cancer Research, understanding the genetic mutations driving BCC has led to targeted therapies like hedgehog pathway inhibitors. These drugs disrupt the signaling pathway implicated in BCC development, offering promising outcomes for patients with advanced or metastatic BCC. Moreover, research into immunotherapies for BCC is gaining traction, harnessing the body's immune system to recognize and destroy cancer cells. Despite advancements, prevention remains crucial, emphasizing sun protection measures and regular skin screenings. Continued research endeavors aim to enhance treatment efficacy, minimize side effects, and ultimately improve the prognosis for individuals affected by basal cell carcinoma.